Treating obesity using glucagon-like peptide-1-directed N-methyl-D-aspartate receptor inhibition Post author: Post published:May 20, 2024 Post category:uncategorized Bimodal drug that successfully cures obesity, hyperglycemia, and dyslipidemia in mouse models. You Might Also Like PFAS chemicals in water and consumer goods linked to rising thyroid cancer rates October 25, 2023 Dopaminergic drug levodopa linked to better sleep in Parkinson’s patients August 13, 2024 GLP-1 therapy boosts visceral fat metabolism, driving weight loss August 26, 2024